



10-Fundamentally Strong Value Stocks Hitting Our Radar

Trying to find value in an over-valued market is difficult to say the least. This becomes even more problematic when we discuss the issue within the reality of a late-stage economic cycle and the potential for an economic recession. So, in looking for opportunity at a time where there is a rising unfavorable economic and earnings backdrop, we turned to our database to screen for stocks with a very strict set of fundamental guidelines. In order for a company to become a watch list candidate it must have:

- **Five-year average returns on equity (ROE) greater than 15%;**
- **Five-year average returns on invested capital (ROIC) greater than 15%;**
- **Debt-to-equity (D/E) less than or equal to 80% of the industry average;**
- **Five-year average pretax profit margin (PM) 20% higher than the industry average;**
- **Current price-to-book value multiples(P/B) below historical and industry multiples;**

- **Current price-to-cash flow (P/CF) ratios below the industry average**




Out of the universe of more than 6,500 issues, only 10 passed the test. This should immediately ring some alarm bells on the market as a whole with respect to valuations and the risk being undertaken by investors in general. However, here are the 10 top stocks we are adding to our watch list currently.

| Company | Ticker | ROE 5 Yr Avg | Invested Capital TTM 5 Yr | Debt / Equity <= 80% Industry Avg. | Pretax Mgn 5 Yr Avg | Book Value Below Industry | Price/ Cash Flow |
|-----------------------------------|--------|-----------------|---------------------------------|--|---------------------------|---------------------------------|------------------------|
| SOAPS-COSMETICS | | | | | | | |
| Colgate Palmoli | CL | 1675.06% | 19.05 | -34.49 | 21.21% | 1.000 | 18.48 |
| HOME FURNISHING-APPLIANCE | | | | | | | |
| Sleep Number Cp | SNBR | 38.48% | 30.13 | 0.00 | 6.89% | 1.000 | 10.79 |
| FOOD/DRUG-RETAIL/WHOLESALE | | | | | | | |
| Denny'S Corp | DENN | 1569.67% | 22.85 | -2.63 | 9.32% | 1.000 | 14.72 |
| Papa Johns Intl | PZZA | 1101.67% | 19.26 | -2.22 | 7.70% | 1.000 | 13.63 |
| DRUGS | | | | | | | |
| Anika Therapeut | ANIK | 16.51% | 15.63 | 0.00 | 49.96% | 1.000 | 17.96 |
| China Biologic | CBPO | 21.35% | 20.79 | 0.00 | 45.00% | 1.000 | 15.64 |
| Taro Pharma Ind | TARO | 28.11% | 32.03 | 0.00 | 60.37% | 1.000 | 14.52 |
| MEDICAL PRODUCTS | | | | | | | |
| Remendent Inc | REMI | 15.64% | 16.20 | 0.00 | 13.18% | 1.000 | 84.43 |
| BUILDING PRODUCTS | | | | | | | |
| Lennox Intl Inc | LII | 50.02% | 25.12 | -7.32 | 9.98% | 1.000 | 20.83 |
| AEROSPACE-DEFENSE | | | | | | | |
| Boeing Co | BA | 571.65% | 20.15 | -7.65 | 7.95% | 1.000 | 23.12 |




***Disclosure: We currently own BA in both our Equity and Equity/ETF portfolio models.**

****While REMI made the screening list, it is excluded from consideration due to being under \$5/share.**



Below I am providing a brief snapshot of each for your own review. **CL**

| COLGATE PALMOLI (CL) | | | | Recommendations | | | |
|--|--|--|--|--|--|--|--|
| Global Sector: Consumer Staples Price: \$63.55 Ind. Dividend Yield: 1.7% Market Cap (\$mil): 55,144.79 | | | | Zacks Rank: 4  | | Average Broker Rating: 2.75  | |
| Price & Volume Data 52 Week High: 77.50 % Price Change 1-Week: -0.44 52 Week Low: 61.65 % Price Change 4-Week: -6.45 50 Day Average: 66.38 % Price Change 12-Week: -3.64 200 Day Average: 68.69 % Price Change MTD: -5.08 Beta (60 Month): 0.72 % Price Change YTD: -19.84 Shares Outstanding (\$mil): 867.74 20 Day Average Volume (000's): 3,644.76 | | | | Annual Earnings EPS Growth Y/Y PE 12/31/2017: 2.87 2.14% 21.25 12/31/2018 Est: 3.00 4.45% 21.20 12/31/2019 Est: 3.16 5.48% 20.10 12/31/2020 Est: 3.34 5.50% 19.05 3-5 Year Growth Rate Est: 7.28 | | | Annual EPS  |
| Other Key Measurements | | | | Estimate Surprise | | | |



SNBR

| SLEEP NUMBER CP (SNBR) | | | | Recommendations | | | |
|--|----------|-------------------------------|--------|--|--------|--|------------|
| Global Sector: Consumer Discretionary Price: \$33.56 Ind. Dividend Yield: 0.0% Market Cap (\$mil): 1,171.01 | | | | Zacks Rank: 1  Strong Sell Strong Buy | | Average Broker Rating: 2.86  Strong Sell Strong Buy | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS |
| 52 Week High: | 40.19 | % Price Change 1-Week: | 1.88 | | EPS | Growth Y/Y | PE |
| 52 Week Low: | 27.14 | % Price Change 4-Week: | -9.00 | 12/31/2017 | 1.49 | 35.45% | 22.52 |
| 50 Day Average: | 34.22 | % Price Change 12-Week: | 8.33 | 12/31/2018 Est | 1.81 | 21.38% | 18.56 |
| 200 Day Average: | 33.54 | % Price Change MTD: | -8.75 | 12/31/2019 Est | 2.27 | 25.59% | 14.77 |
| Beta (60 Month): | 1.16 | % Price Change YTD: | -15.03 | 12/31/2020 Est | 2.73 | 20.19% | 12.29 |
| Shares Outstanding (\$mil) | 34.89 | 20 Day Average Volume (000's) | 512.43 | 3-5 Year Growth Rate Est. | 18.42 | | |
| Other Key Measurements | | | | Estimate Surprise | | | |
| | Current | 5-Year Median | |  #LinkError 09/30/16 12/31/16 03/31/17 06/30/17 09/30/17 12/31/17 03/31/18 | | | |
| Price/Book Value | -55.37 | 5.66 | | | | | |
| PE F12M Est | 15.41 | 16.59 | | | | | |
| Price/EBITDA | 8.59 | 8.88 | | | | | |
| | Current | 5-Year Median | | | | | |
| Pre-Tax Margin TTM | 5.82 | 6.57 | | Peer Comparison | | | |
| Net Prof Margin TTM | 4.10 | 5.00 | | | | | |
| Current Ratio | 0.39 | 0.80 | | | | | |
| ROE TTM | 115.80 | 30.13 | | | | | |
| ROC TTM | 115.80 | 30.13 | | | | | |
| LT Debt/ Equity | 0.00 | 0.00 | | | | | |
| LT Debt/ Total Cap | 0.00 | 0.00 | | | | | |
| Equity/Assets | -2223.46 | 241.13 | | | | | |
| | | | | PE TTM | PE F12 | P/FCF | EPS GRE |
| SLEEP NUMBER CP (SNBR) | | | | 22.52 | 15.41 | 20.96 | 18.42 |
| S&P 500 MARKET WEIGHTED COMPOSITE | | | | 19.44 | 16.78 | 22.55 | 9.78 |
| S&P 500 CONSUMER DISCRETIONARY COMPOS | | | | 25.76 | 21.16 | 9.41 | 26.82 |
| | | | | | | | 9.41 |
| | | | | | | | 45.62 |

DENN



| DENNY'S CORP (DENN) | | | | Recommendations | | | |
|--|-------|-------------------------------|--------|---|------|--|------------|
| Global Sector: Consumer Discretionary Price: \$14.66 Ind. Dividend Yield: 0.0% Market Cap (\$mil): 929.24 | | | | Zacks Rank: 2  Strong Sell Strong Buy | | Average Broker Rating: 2.33  Strong Sell Strong Buy | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS |
| 52 Week High: | 17.51 | % Price Change 1-Week: | 3.60 | | EPS | Growth Y/Y | PE |
| 52 Week Low: | 12.23 | % Price Change 4-Week: | 5.24 | 12/31/2017 | 0.58 | 5.45% | 22.55 |
| 50 Day Average: | 14.57 | % Price Change 12-Week: | -5.66 | 12/31/2018 Est | 0.68 | 17.24% | 21.56 |
| 200 Day Average: | 14.89 | % Price Change MTD: | -0.41 | 12/31/2019 Est | 0.75 | 9.56% | 19.68 |
| Beta (60 Month): | 0.45 | % Price Change YTD: | 5.38 | 12/31/2020 Est | | | |
| Shares Outstanding (\$mil) | 63.39 | 20 Day Average Volume (000's) | 352.74 | 3-5 Year Growth Rate Est. | | | |
| Other Key Measurements | | | | Estimate Surprise | | | |

PZZA


| PAPA JOHNS INTL (PZZA) | | | | Recommendations | | | | | | |
|---------------------------------------|---------|-------------------------------|----------|---|--------|---|---|---------|----------|---------|
| Global Sector: Consumer Discretionary | | | | Zacks Rank: 5 | | Average Broker Rating: 1.67 | | | | |
| Price: \$53.82 | | | |  | |  | | | | |
| Ind. Dividend Yield: 0.9% | | | | Strong Sell | | Strong Buy | | | | |
| Market Cap (\$mil): 1,701.77 | | | | | | | | | | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS  | | | |
| 52 Week High: | 70.64 | % Price Change 1-Week: | -0.35 | | EPS | Growth Y/Y | | PE | | |
| 52 Week Low: | 38.94 | % Price Change 4-Week: | 15.49 | 12/31/2017 | 2.62 | 2.75% | | 24.03 | | |
| 50 Day Average: | 47.12 | % Price Change 12-Week: | 20.46 | 12/31/2018 Est | 1.51 | -42.37% | | 35.64 | | |
| 200 Day Average: | 54.60 | % Price Change MTD: | 4.95 | 12/31/2019 Est | 1.68 | 11.48% | | 31.97 | | |
| Beta (60 Month): | 0.44 | % Price Change YTD: | -8.71 | 12/31/2020 Est | 2.87 | 70.50% | | 18.75 | | |
| Shares Outstanding (\$mil) | 31.62 | 20 Day Average Volume (000's) | 1,606.16 | 3-5 Year Growth Rate Est. | 12.50 | | | | | |
| Other Key Measurements | | | | Estimate Surprise | | | | | | |
| | Current | 5-Year Median | |  | | | | | | |
| Price/Book Value | -6.80 | 15.80 | | | | | | | | |
| PE F12M Est | 32.65 | 25.31 | | | | | | | | |
| Price/EBITDA | 10.55 | 14.37 | | | | | | | | |
| | Current | 5-Year Median | | Peer Comparison | | | | | | |
| Pre-Tax Margin TTM | 6.06 | 7.35 | | PAPA JOHNS INTL (PZZA) | PE TTM | PE F12 | P/FCF | EPS GRE | Price/BV | ROE TTM |
| Net Prof Margin TTM | 4.45 | 4.98 | | S&P 500 MARKET WEIGHTED COMPOSITE | 19.44 | 16.78 | 22.55 | 9.78 | 3.95 | 17.15 |
| Current Ratio | 1.08 | 1.28 | | S&P 500 CONSUMER DISCRETIONARY COMPOS | 25.76 | 21.16 | 9.41 | 26.82 | 9.41 | 45.62 |
| ROE TTM | -47.37 | 79.39 | | | | | | | | |
| ROC TTM | 23.76 | 26.46 | | | | | | | | |
| LT Debt/ Equity | -222.21 | 204.83 | | | | | | | | |
| LT Debt/ Total Cap | | 89.48 | | | | | | | | |
| Equity/Assets | -222.92 | 460.28 | | | | | | | | |

- Warning:** The company is facing numerous class action lawsuits which could have an adverse effect on the company.



ANIK

| ANIKA THERAPEUT (ANIK) | | | | Recommendations | | | |
|---|-------|-------------------------|-------|--|------|--|------------|
| Global Sector: Health Care Price: \$41.40 Ind. Dividend Yield: 0.0% Market Cap (\$mil): 603.76 | | | | <u>Zacks Rank: 2</u>  | | <u>Average Broker Rating: 2</u>  | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS |
| 52 Week High: | 68.43 | % Price Change 1-Week: | 1.64 | | EPS | Growth Y/Y | PE |
| 52 Week Low: | 28.77 | % Price Change 4-Week: | 2.20 | 12/31/2017 | 1.96 | -8.84% | 25.40 |
| 50 Day Average: | 41.61 | % Price Change 12-Week: | 21.84 | 12/31/2018 Est | 1.55 | -20.92% | 26.71 |
| 200 Day Average: | 46.80 | % Price Change MTD: | -1.85 | 12/31/2019 Est | 1.49 | -4.19% | 27.88 |




CBPO

| CHINA BIOLOGIC (CBPO) | | | | Recommendations | | | | | |
|---|---------|-------------------------------|--------|---|--------|--|------------|----------|---------|
| Global Sector: Health Care Price: \$72.76 Ind. Dividend Yield: 0.0% Market Cap (\$mil): 2,410.75 | | | | Zacks Rank: 3  Strong Sell Strong Buy | | Average Broker Rating: 1.67  Strong Sell Strong Buy | | | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS | | |
| 52 Week High: | 106.72 | % Price Change 1-Week: | -1.76 | | EPS | Growth Y/Y | PE | | |
| 52 Week Low: | 72.76 | % Price Change 4-Week: | -10.98 | 12/31/2017 | 4.95 | 32.35% | 16.57 | | |
| 50 Day Average: | 84.69 | % Price Change 12-Week: | -29.37 | 12/31/2018 Est | 3.71 | -25.05% | 19.61 | | |
| 200 Day Average: | 85.34 | % Price Change MTD: | -9.05 | 12/31/2019 Est | 4.82 | 29.92% | 15.10 | | |
| Beta (60 Month): | 1.18 | % Price Change YTD: | -12.09 | 12/31/2020 Est | 5.28 | 9.54% | 13.78 | | |
| Shares Outstanding (\$mil) | 33.13 | 20 Day Average Volume (000's) | 227.46 | 3-5 Year Growth Rate Est. | 13.00 | | | | |
| Other Key Measurements | | | | Estimate Surprise | | | | | |
| | Current | 5-Year Median | |  | | | | | |
| Price/Book Value | 1.95 | 5.12 | | | | | | | |
| PE F12M Est | 15.83 | 21.21 | | | | | | | |
| Price/EBITDA | 11.85 | 19.41 | | | | | | | |
| | Current | 5-Year Median | | | | | | | |
| Pre-Tax Margin TTM | 35.14 | 45.31 | | | | | | | |
| Net Prof Margin TTM | 32.91 | 30.00 | | | | | | | |
| Current Ratio | 6.25 | 5.36 | | | | | | | |
| ROE TTM | 14.00 | 21.40 | | | | | | | |
| ROC TTM | 14.66 | 20.79 | | | | | | | |
| LT Debt/ Equity | 0.00 | 0.00 | | | | | | | |
| LT Debt/ Total Cap | 0.00 | 0.00 | | | | | | | |
| Equity/Assets | 113.57 | 117.84 | | | | | | | |
| | | | | Peer Comparison | | | | | |
| | | | | PE TTM | PE F12 | P/FCF | EPS GRE | Price/BV | ROE TTM |
| CHINA BIOLOGIC (CBPO) | | | | 16.57 | 15.83 | 34.21 | 13.00 | 1.95 | 14.66 |
| S&P 500 MARKET WEIGHTED COMPOSITE | | | | 19.44 | 16.78 | 22.55 | 9.78 | 3.95 | 17.15 |
| S&P 500 HEALTH CARE COMPOSITE | | | | 18.57 | 16.50 | 6.75 | 27.55 | 6.75 | 27.64 |

TARO

| TARO PHARMA IND (TARO) | | | | Recommendations | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--------|-------------------------------|--------|--|----------|---|------------|--|--------|--------|-------|---------|----------|---------|-----------------------|-------|-------|-------|-------|------|-------|-----------------------------------|-------|-------|-------|------|------|-------|-------------------------------|-------|-------|------|-------|------|-------|
| Global Sector: Health Care Price: \$97.37 Ind. Dividend Yield: 0.0% Market Cap (\$mil): 3,839.01 | | | | Zacks Rank: 3  Strong Sell Strong Buy | | Average Broker Rating: 1  Strong Sell Strong Buy | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 52 Week High: | 126.38 | % Price Change 1-Week: | -1.09 | | EPS | Growth Y/Y | PE | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 52 Week Low: | 94.74 | % Price Change 4-Week: | -1.68 | 3/31/2018 | 6.18 | -44.12% | 14.87 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 50 Day Average: | 102.00 | % Price Change 12-Week: | -14.72 | 3/31/2019 Est | 7.65 | 23.79% | 12.73 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 200 Day Average: | 106.57 | % Price Change MTD: | -0.95 | 3/31/2020 Est | 11.16 | 45.88% | 8.72 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Beta (60 Month): | 0.43 | % Price Change YTD: | -11.50 | 3/31/2021 Est | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Shares Outstanding (\$mil) | 39.43 | 20 Day Average Volume (000's) | 48.24 | 3-5 Year Growth Rate Est. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other Key Measurements | | | | Estimate Surprise | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Price/Book Value | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PE F12M Est | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Price/EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Pre-Tax Margin TTM | | | | Peer Comparison | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | <table><tr><th></th><th>PE TTM</th><th>PE F12</th><th>P/FCF</th><th>EPS GRE</th><th>Price/BV</th><th>ROE TTM</th></tr><tr><td>CHINA BIOLOGIC (CBPO)</td><td>16.57</td><td>15.83</td><td>34.21</td><td>13.00</td><td>1.95</td><td>14.66</td></tr><tr><td>S&P 500 MARKET WEIGHTED COMPOSITE</td><td>19.44</td><td>16.78</td><td>22.55</td><td>9.78</td><td>3.95</td><td>17.15</td></tr><tr><td>S&P 500 HEALTH CARE COMPOSITE</td><td>18.57</td><td>16.50</td><td>6.75</td><td>27.55</td><td>6.75</td><td>27.64</td></tr></table> | | | | | PE TTM | PE F12 | P/FCF | EPS GRE | Price/BV | ROE TTM | CHINA BIOLOGIC (CBPO) | 16.57 | 15.83 | 34.21 | 13.00 | 1.95 | 14.66 | S&P 500 MARKET WEIGHTED COMPOSITE | 19.44 | 16.78 | 22.55 | 9.78 | 3.95 | 17.15 | S&P 500 HEALTH CARE COMPOSITE | 18.57 | 16.50 | 6.75 | 27.55 | 6.75 | 27.64 |
| | PE TTM | PE F12 | P/FCF | EPS GRE | Price/BV | ROE TTM | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| CHINA BIOLOGIC (CBPO) | 16.57 | 15.83 | 34.21 | 13.00 | 1.95 | 14.66 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| S&P 500 MARKET WEIGHTED COMPOSITE | 19.44 | 16.78 | 22.55 | 9.78 | 3.95 | 17.15 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| S&P 500 HEALTH CARE COMPOSITE | 18.57 | 16.50 | 6.75 | 27.55 | 6.75 | 27.64 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net Prof Margin TTM | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Current Ratio | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ROE TTM | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ROC TTM | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| LT Debt/ Equity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| LT Debt/ Total Cap | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Equity/Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

REMI

| REMENTENT INC (REMI) | | | | Recommendations | | | |
|----------------------------|---------|-------------------------------|--------|---|------------|---|---|
| Global Sector: Health Care | | | | Zacks Rank: 3 | | Broker Rating Not Available | |
| Price: \$0.19 | | | |  | |  | |
| Ind. Dividend Yield: 0.0% | | | | Strong Sell | | Strong Buy | |
| Market Cap (\$mil): 3.80 | | | | Strong Sell | | Strong Buy | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS  |
| 52 Week High: | 0.34 | % Price Change 1-Week: | -5.00 | EPS | Growth Y/Y | PE | |
| 52 Week Low: | 0.18 | % Price Change 4-Week: | -9.52 | 3/31/2018 | 0.00 | | |
| 50 Day Average: | 0.22 | % Price Change 12-Week: | 0.00 | 3/31/2019 Est | 0.02 | 9.50 | |
| 200 Day Average: | 0.24 | % Price Change MTD: | -5.00 | 3/31/2020 Est | 0.02 | 0.00% 9.50 | |
| Beta (60 Month): | 0.24 | % Price Change YTD: | -46.81 | 3/31/2021 Est | 0.03 | 25.00% 7.60 | |
| Shares Outstanding (\$mil) | 20.00 | 20 Day Average Volume (000's) | 0.28 | 3-5 Year Growth Rate Est. | | | |
| Other Key Measurements | | | | Estimate Surprise | | | |
| | Current | 5-Year Median | |  | | | |
| Price/Book Value | 1.20 | 1.76 | | | | | |
| PE F12M Est | 9.50 | | | | | | |
| Price/EBITDA | -10.19 | 4.04 | | | | | |
| | Current | 5-Year Median | | Peer Comparison | | | |
| Pre-Tax Margin TTM | -10.67 | 14.12 | | PE TTM | PE F12 | P/FCF | EPS GRE |
| Net Prof Margin TTM | -11.78 | 11.47 | | | | | Price/BV |
| Current Ratio | 0.71 | 0.84 | | | | | ROE TTM |
| ROE TTM | -8.39 | | | REMENTENT INC (REMI) | -19.00 | -984.00 | #LinkError |
| ROC TTM | -8.39 | 16.20 | | \$S&P 500 MARKET WEIGHTED COMPOSITE | 19.44 | 16.78 | 22.55 |
| LT Debt/ Equity | 0.00 | 0.00 | | | | | 9.78 |
| LT Debt/ Total Cap | 0.00 | 0.00 | | | | | 3.95 |
| Equity/Assets | 166.33 | 239.39 | | | | | 17.15 |
| | | | | \$S&P 500 HEALTH CARE COMPOSITE | 18.57 | 16.50 | 6.75 |
| | | | | | | | 27.55 |
| | | | | | | | 6.75 |
| | | | | | | | 27.64 |

- Warning:** This is a sub-\$5 stock and is extremely high risk. It is not suitable for investors or our portfolios.

LII

| LENNOX INTL IN LII | | | NYSE | | | Industry: BLDG PROD-AIR COND/HEAT | | | |
|--------------------|------|-----------------|-------------------|-------|--------------|-----------------------------------|---------|--------|------------|
| Rec Price | P/E | Mkt Cap (\$mil) | Div Rate | Yield | Sales (12Mo) | Sls Gr | EPS Gr | Div Gr | Zacks Rank |
| \$200.74 | 22.3 | \$8,080.9 | \$2.56 | 1.3% | \$3,954 | 5% | 23% | 21% | Hold |
| Ave Broker Rec | | | Price/Volume Data | | | EPS, P/E and Growth Rates | | | Yr/Yr |
| Buy | | | 52-Wk | High | \$228.62 | FY | EPS | P/E | EPS Gr |
| | | | | Low | \$179.39 | 12/17 Act | 7.92 | 22.28 | 14% |
| | | | PriceChg-YTD | | -3.6% | 12/18 Est | 9.22 | 21.78 | 16% |
| | | | -YTD(Rel) | | -8.3% | 12/19 Est | 11.61 | 17.29 | 26% |
| | | | Avg Dly Vol (Mil) | | 322 | Last 5 yr | | | 23% |
| | | | Exp Return/Risk | | | Next 3-5Yr (Est) | | | 19% |
| | | | Impl Ret=Yld+Gr | | 0.20 | Other Key Measures | | | 5-Year |
| | | | Beta | | 1.14 | | Current | | Avg |
| | | | Shareholder Data | | | P/E (12 Mo) | 22.3 | | 23.8 |
| | | | Shares Out | | 40.26 | Rel P/E | 111% | | |
| | | | Institutions | | 68.34% | Net Margin | 8% | | 6.7% |
| | | | Insiders | | 3.90% | ROE | -750.6% | | 50.0% |
| | | | | | | LT Debt/Cap | | | 79% |

BA

| BOEING CO (BA) | | | | Recommendations | | | |
|--|----------|-------------------------------|----------|---|---------|--|------------|
| Global Sector: Industrials Price: \$365.50 Ind. Dividend Yield: 6.8% Market Cap (\$mil): 209,982.78 | | | | Zacks Rank: 3  Strong Sell Strong Buy | | Average Broker Rating: 1.47  Strong Sell Strong Buy | |
| Price & Volume Data | | | | Annual Earnings | | | Annual EPS |
| 52 Week High: | 392.30 | % Price Change 1-Week: | -0.54 | | EPS | Y/Y | PE |
| 52 Week Low: | 256.46 | % Price Change 4-Week: | 0.08 | 12/31/2017 | 12.04 | 55.96% | 25.22 |
| 50 Day Average: | 358.48 | % Price Change 12-Week: | 2.69 | 12/31/2018 Est | 14.58 | 21.09% | 25.07 |
| 200 Day Average: | 334.55 | % Price Change MTD: | -1.72 | 12/31/2019 Est | 17.43 | 19.57% | 20.97 |
| Beta (60 Month): | 1.40 | % Price Change YTD: | 17.95 | 12/31/2020 Est | 20.54 | 17.83% | 17.79 |
| Shares Outstanding (\$mil) | 574.51 | 20 Day Average Volume (000's) | 3,909.18 | 3-5 Year Growth Rate Est. | 13.75 | | |
| Other Key Measurements | | | | Estimate Surprise | | | |
| | Current | 5-Year Median | |  | | | |
| Price/Book Value | -152.83 | 14.22 | | | | | |
| PE F12M Est | 21.69 | 16.79 | | | | | |
| Price/EBITDA | 17.27 | 11.05 | | | | | |
| | Current | 5-Year Median | | Peer Comparison | | | |
| Pre-Tax Margin TTM | 11.16 | 7.65 | | | PE TTM | PE F12 | P/FCF |
| Net Prof Margin TTM | 9.04 | 6.38 | | BOEING CO (BA) | 25.22 | 21.80 | 17.05 |
| Current Ratio | 1.11 | 1.23 | | S&P 500 MARKET WEIGHTED COMPOSITE | 19.44 | 16.78 | 22.55 |
| ROE TTM | 2344.87 | 81.14 | | S&P 500 INDUSTRIALS COMPOSITE | 18.75 | 15.78 | 8.59 |
| ROC TTM | 82.64 | 34.72 | | | EPS GRE | Price/BV | ROE TTM |
| LT Debt/ Equity | -764.70 | 138.82 | | | 13.75 | -152.83 | 2344.87 |
| LT Debt/ Total Cap | 88.97 | 59.06 | | | 9.78 | 3.95 | 17.15 |
| Equity/Assets | -8238.36 | 1515.63 | | | 14.44 | 8.59 | 64.23 |

Importantly, just because these companies cleared a screen, such is only the first step in determining if it should be added to an investment portfolio. Each company must be evaluated not only on its fundamental merits but its price trends as well. They should also be evaluated relative to other holdings in your portfolio, your own personal risk tolerance, and your investment objectives. **Disclaimer:** As always, you must do your homework *BEFORE* making any investment. The information contained herein should not be construed as investment advice or a solicitation to buy or sell any security. Past performance is no guarantee of future results. Use of this information is at your own risk and peril. •